Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7PCLY)

• Drug Name: ARC1779 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Intracranial embolism	8B22.1	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM7PCLY

Molecule-Related Drug Atlas

Drug(s) Targeting von Willebrand factor (VWF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vonvendi	DMI783H	Von willebrand disease	3B12	Approved	[3]
Caplacizumab	DMPUKA7	Thrombotic thrombocytopenic purpura	3B64.14	Approved	[4]
Recombinant von Willebrand factor/recombinant Factor VIII complex	DM7JFDO	Von willebrand disease	3B12	Phase 3	[5]
ALX-0081	DM7EBH9	Thrombotic thrombocytopenic purpura	3B64.14	Phase 3	[6]
BT-200	DM1EYOF	Von willebrand disease	3B12	Phase 2	[7]
DA-697b	DMBRN2G	Thrombosis	DB61-GB90	Phase 1	[8]
DTRI-031	DM0BCT7	Ischemic stroke	8B11.5Z	Phase 1	[9]
Mitoflaxone	DMO06JV	Solid tumour/cancer	2A00-2F9Z	Terminated	[10]
Auryntricarboxylic acid (ATA)	DMOIQ4K	Discovery agent	N.A.	Investigative	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
von Willebrand factor (VWF)	TT3SZBT	VWF_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT00742612) Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy. U.S. National Institutes of Health.
• [2] Short-Acting Anti-VWF (von Willebrand Factor) Aptamer Improves the Recovery, Survival, and Hemostatic Functions of Refrigerated Platelets. Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2028-2037.
• [3] Clinical pipeline report, company report or official report of Vonvendi.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [5] 6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009 December; 36(6): 409-418.
• [6] Clinical pipeline report, company report or official report of Ablynx
• [7] Clinical pipeline report, company report or official report of Guardian Theapeutics
• [8] A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost. 2010 Jan;103(1):205-12.
• [9] Clinical pipeline report, company report or official report of Basking Biosciences
• [10] Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.